CYP2D6 metabolism. Minor/Significance Unknown.chloroquine increases levels of prochlorperazine by decreasing metabolism. Minor/Significance Unknown.cimetidinecimetidine will increase the level or effect of prochlorperazine by affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown.clomipramineclomipramine, prochlorperazine. Either increases levels of the other by decreasing metabolism. Minor/Significance Unknown. Additive anticholinergic effects.clomipramine, prochlorperazine. Either increases levels of the other by pharmacodynamic synergism. Minor/Significance Unknown. Additive anticholinergic effects.darifenacindarifenacin will increase the level or effect of prochlorperazine by affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown.desipraminedesipramine, prochlorperazine. Either increases levels of the other by decreasing metabolism. Minor/Significance Unknown. Additive anticholinergic effects.desipramine, prochlorperazine. Either increases levels of the other by pharmacodynamic synergism. Minor/Significance Unknown. Additive anticholinergic effects.diphenhydraminediphenhydramine will increase the level or effect of prochlorperazine by affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown.doxepindoxepin, prochlorperazine. Either increases levels of the other by decreasing metabolism. Minor/Significance Unknown. Additive anticholinergic effects.doxepin, prochlorperazine. Either increases levels of the other by pharmacodynamic synergism. Minor/Significance Unknown. Additive anticholinergic effects.dronedaronedronedarone will increase the level or effect of prochlorperazine by affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown.duloxetineduloxetine will increase the level or effect of prochlorperazine by affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown.enalaprilprochlorperazine increases effects of enalapril by unspecified interaction mechanism. Minor/Significance Unknown.ethanolethanol, prochlorperazine. Either increases toxicity of the other by pharmacodynamic synergism. Minor/Significance Unknown. Additive CNS depression.eucalyptusprochlorperazine and eucalyptus both increase sedation. Minor/Significance Unknown.fosinoprilprochlorperazine increases effects of fosinopril by unspecified interaction mechanism. Minor/Significance Unknown.glycopyrrolateprochlorperazine increases toxicity of glycopyrrolate by unknown mechanism. Minor/Significance Unknown.glycopyrrolate inhaledprochlorperazine increases toxicity of glycopyrrolate inhaled by unknown mechanism. Minor/Significance Unknown.haloperidolhaloperidol will increase the level or effect of prochlorperazine by affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown.imatinibimatinib will increase the level or effect of prochlorperazine by affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown.imidaprilprochlorperazine increases effects of imidapril by unspecified interaction mechanism. Minor/Significance Unknown.imipramineimipramine, prochlorperazine. Either increases levels of the other by decreasing metabolism. Minor/Significance Unknown. Additive anticholinergic effects.imipramine, prochlorperazine. Either increases levels of the other by pharmacodynamic synergism. Minor/Significance Unknown. Additive anticholinergic effects.lisinoprilprochlorperazine increases effects of lisinopril by unspecified interaction mechanism. Minor/Significance Unknown.lofepraminelofepramine, prochlorperazine. Either increases levels of the other by decreasing metabolism. Minor/Significance Unknown. Additive anticholinergic effects.lofepramine, prochlorperazine. Either increases levels of the other by pharmacodynamic synergism. Minor/Significance Unknown. Additive anticholinergic effects.maprotilinemaprotiline, prochlorperazine. Either increases levels of the other by decreasing metabolism. Minor/Significance Unknown. Additive anticholinergic effects.maprotiline, prochlorperazine. Either increases levels of the other by pharmacodynamic synergism. Minor/Significance Unknown. Additive anticholinergic effects.maravirocmaraviroc will increase the level or effect of prochlorperazine by affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown.marijuanamarijuana will increase the level or effect of prochlorperazine by affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown.metyraponeprochlorperazine decreases effects of metyrapone by unspecified interaction mechanism. Minor/Significance Unknown.metyrosinemetyrosine increases toxicity of prochlorperazine by pharmacodynamic synergism. Minor/Significance Unknown. Increased extrapyramidal symptoms.moexiprilprochlorperazine increases effects of moexipril by unspecified interaction mechanism. Minor/Significance Unknown.nilotinibnilotinib will increase the level or effect of prochlorperazine by affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown.nortriptylinenortriptyline, prochlorperazine. Either increases levels of the other by decreasing metabolism. Minor/Significance Unknown. Additive anticholinergic effects.nortriptyline, prochlorperazine. Either increases levels of the other by pharmacodynamic synergism. Minor/Significance Unknown. Additive anticholinergic effects.oxybutyninoxybutynin increases toxicity of prochlorperazine by unspecified interaction mechanism. Minor/Significance Unknown.oxybutynin topicaloxybutynin topical increases toxicity of prochlorperazine by unspecified interaction mechanism. Minor/Significance Unknown.oxybutynin transdermaloxybutynin transdermal increases toxicity of prochlorperazine by unspecified interaction mechanism. Minor/Significance Unknown.parecoxibparecoxib will increase the level or effect of prochlorperazine by affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown.perindoprilprochlorperazine increases effects of perindopril by unspecified interaction mechanism. Minor/Significance Unknown.perphenazineperphenazine will increase the level or effect of prochlorperazine by affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown.protriptylineprotriptyline, prochlorperazine. Either increases levels of the other by decreasing metabolism. Minor/Significance Unknown. Additive anticholinergic effects.protriptyline, prochlorperazine. Either increases levels of the other by pharmacodynamic synergism. Minor/Significance Unknown. Additive anticholinergic effects.pyrimethaminepyrimethamine increases levels of prochlorperazine by decreasing metabolism. Minor/Significance Unknown.quinacrinequinacrine will increase the level or effect of prochlorperazine by affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown.quinaprilprochlorperazine increases effects of quinapril by unspecified interaction mechanism. Minor/Significance Unknown.ramiprilprochlorperazine increases effects of ramipril by unspecified interaction mechanism. Minor/Significance Unknown.ranolazineranolazine will increase the level or effect of prochlorperazine by affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown.ritonavirritonavir will increase the level or effect of prochlorperazine by affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown.sageprochlorperazine and sage both increase sedation. Minor/Significance Unknown.sertralinesertraline will increase the level or effect of prochlorperazine by affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown.thioridazinethioridazine will increase the level or effect of prochlorperazine by affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown.tipranavirtipranavir will increase the level or effect of prochlorperazine by affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown.trandolaprilprochlorperazine increases effects of trandolapril by unspecified interaction mechanism. Minor/Significance Unknown.trazodonetrazodone, prochlorperazine. Either increases toxicity of the other by pharmacodynamic synergism. Minor/Significance Unknown. Additive hypotensive effects.trazodone, prochlorperazine. Either increases levels of the other by decreasing metabolism. Minor/Significance Unknown. Additive anticholinergic effects.trimipraminetrimipramine, prochlorperazine. Either increases levels of the other by decreasing metabolism. Minor/Significance Unknown. Additive anticholinergic effects.trimipramine, prochlorperazine. Either increases levels of the other by pharmacodynamic synergism. Minor/Significance Unknown. Additive anticholinergic effects.abobotulinumtoxinAMonitor Closely (1)abobotulinumtoxinA increases effects of prochlorperazine by pharmacodynamic synergism. Use Caution/Monitor. Use of anticholinergic drugs after administration of botulinum toxin-containing products may potentiate systemic anticholinergic effects.aclidiniumMonitor Closely (2)aclidinium decreases levels of prochlorperazine by pharmacodynamic antagonism. Use Caution/Monitor. prochlorperazine increases effects of aclidinium by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.acrivastineMonitor Closely (1)acrivastine and prochlorperazine both increase sedation. Use Caution/Monitor.albiglutideMonitor Closely (1)prochlorperazine, albiglutide. Other (see comment). Use Caution/Monitor. Comment: Phenothiazines may increase or decrease glucose levels, monitor therapy closely when these agents are concurrently administered.albuterolMonitor Closely (1)prochlorperazine increases and albuterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.alfentanilMonitor Closely (1)alfentanil and prochlorperazine both increase sedation. Use Caution/Monitor.alprazolamMonitor Closely (1)alprazolam and prochlorperazine both increase sedation. Use Caution/Monitor.amifampridineMonitor Closely (1)prochlorperazine increases toxicity of amifampridine by Other (see comment). Modify Therapy/Monitor Closely. Comment: Amifampridine can cause seizures. Coadministration with drugs that lower seizure threshold may increase this risk.aminolevulinic acid oralSerious - Use Alternative (1)aminolevulinic acid oral, prochlorperazine. Either increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Avoid administering other phototoxic drugs with aminolevulinic acid oral for 24 hr during perioperative period.aminolevulinic acid topicalSerious - Use Alternative (1)prochlorperazine increases toxicity of aminolevulinic acid topical by pharmacodynamic synergism. Avoid or Use Alternate Drug. Coadministration of photosensitizing drugs may enhance the phototoxic reaction to photodynamic therapy with aminolevulinic acid.amiodaroneSerious - Use Alternative (1)prochlorperazine and amiodarone both increase QTc interval. Avoid or Use Alternate Drug.Minor (1)amiodarone will increase the level or effect of prochlorperazine by affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown.amisulprideContraindicated (1)amisulpride, prochlorperazine. Either increases toxicity of the other by Other (see comment). Contraindicated. Comment: Increases risk of neuroleptic malignant syndrome.Monitor Closely (1)prochlorperazine and amisulpride both increase QTc interval. Use Caution/Monitor. ECG monitoring is recommended if coadministered.amitriptylineMonitor Closely (2)prochlorperazine and amitriptyline both increase QTc interval. Use Caution/Monitor. prochlorperazine and amitriptyline both increase sedation. Use Caution/Monitor.Minor (2)amitriptyline, prochlorperazine. Either increases levels of the other by decreasing metabolism. Minor/Significance Unknown. Additive anticholinergic effects. amitriptyline, prochlorperazine. Either increases levels of the other by pharmacodynamic synergism. Minor/Significance Unknown. Additive anticholinergic effects.amobarbitalMonitor Closely (1)amobarbital and prochlorperazine both increase sedation. Use Caution/Monitor.amoxapineMonitor Closely (3)prochlorperazine and amoxapine both increase QTc interval. Use Caution/Monitor. prochlorperazine and amoxapine both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor. prochlorperazine and amoxapine both increase sedation. Use Caution/Monitor.Minor (2)amoxapine, prochlorperazine. Either increases levels of the other by decreasing metabolism. Minor/Significance Unknown. Additive anticholinergic effects. amoxapine, prochlorperazine. Either increases levels of the other by pharmacodynamic synergism. Minor/Significance Unknown. Additive anticholinergic effects.anagrelideMonitor Closely (1)anagrelide and prochlorperazine both decrease QTc interval. Use Caution/Monitor.anticholinergic/sedative combosMonitor Closely (3)anticholinergic/sedative combos decreases levels of prochlorperazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. anticholinergic/sedative combos decreases levels of prochlorperazine by pharmacodynamic antagonism. Use Caution/Monitor. prochlorperazine increases effects of anticholinergic/sedative combos by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.apomorphineMonitor Closely (1)prochlorperazine and apomorphine both increase sedation. Use Caution/Monitor.Serious - Use Alternative (1)prochlorperazine decreases effects of apomorphine by pharmacodynamic antagonism. Avoid or Use Alternate Drug.arformoterolMonitor Closely (1)prochlorperazine increases and arformoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.aripiprazoleMonitor Closely (2)aripiprazole and prochlorperazine both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor. aripiprazole and prochlorperazine both increase sedation. Use Caution/Monitor.armodafinilMonitor Closely (1)prochlorperazine increases and armodafinil decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.arsenic trioxideSerious - Use Alternative (1)prochlorperazine and arsenic trioxide both increase QTc interval. Avoid or Use Alternate Drug.artemether/lumefantrineMonitor Closely (1)artemether/lumefantrine will increase the level or effect of prochlorperazine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.Serious - Use Alternative (1)prochlorperazine and artemether/lumefantrine both increase QTc interval. Avoid or Use Alternate Drug.asenapineMonitor Closely (2)asenapine and prochlorperazine both decrease QTc interval. Use Caution/Monitor. asenapine and prochlorperazine both increase sedation. Use Caution/Monitor.Minor (1)asenapine will increase the level or effect of prochlorperazine by affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown.asenapine transdermalMonitor Closely (2)asenapine transdermal and prochlorperazine both decrease QTc interval. Use Caution/Monitor. asenapine transdermal and prochlorperazine both increase sedation. Use Caution/Monitor.atracuriumMonitor Closely (3)atracurium decreases levels of prochlorperazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. atracurium decreases levels of prochlorperazine by pharmacodynamic antagonism. Use Caution/Monitor. prochlorperazine increases effects of atracurium by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.atropineMonitor Closely (3)atropine decreases levels of prochlorperazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. atropine decreases levels of prochlorperazine by pharmacodynamic antagonism. Use Caution/Monitor. prochlorperazine increases effects of atropine by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.Minor (1)prochlorperazine increases toxicity of atropine by unknown mechanism. Minor/Significance Unknown.atropine IV/IMMonitor Closely (3)prochlorperazine increases effects of atropine IV/IM by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia. atropine IV/IM decreases levels of prochlorperazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. atropine IV/IM decreases levels of prochlorperazine by pharmacodynamic antagonism. Use Caution/Monitor.Minor (1)prochlorperazine increases toxicity of atropine IV/IM by unknown mechanism. Minor/Significance Unknown.avapritinibMonitor Closely (1)avapritinib and prochlorperazine both increase sedation. Use Caution/Monitor.azelastineMonitor Closely (1)azelastine and prochlorperazine both increase sedation. Use Caution/Monitor.azithromycinMonitor Closely (1)prochlorperazine and azithromycin both increase QTc interval. Use Caution/Monitor.baclofenMonitor Closely (1)baclofen and prochlorperazine both increase sedation. Use Caution/Monitor.belladonna alkaloidsMonitor Closely (3)belladonna alkaloids decreases levels of prochlorperazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. belladonna alkaloids decreases levels of prochlorperazine by pharmacodynamic antagonism. Use Caution/Monitor. prochlorperazine increases effects of belladonna alkaloids by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.belladonna and opiumMonitor Closely (4)belladonna and opium decreases levels of prochlorperazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. belladonna and opium decreases levels of prochlorperazine by pharmacodynamic antagonism. Use Caution/Monitor. prochlorperazine increases effects of belladonna and opium by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia. belladonna and opium and prochlorperazine both increase sedation. Use Caution/Monitor.benazeprilMinor (1)prochlorperazine increases effects of benazepril by unspecified interaction mechanism. Minor/Significance Unknown. Enhanced hypotensive effects.benperidolMonitor Closely (2)benperidol and prochlorperazine both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor. benperidol and prochlorperazine both increase sedation. Use Caution/Monitor.benzhydrocodone/acetaminophenSerious - Use Alternative (2)benzhydrocodone/acetaminophen, prochlorperazine. Either increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Profound sedation, respiratory depression, coma, and death may result if coadministered. Reserve concomitant prescribing of these drugs in patients for whom other treatment options are inadequate. Limit dosages and durations to the minimum required. Monitor closely for signs of respiratory depression and sedation. Increased risk of hypotension if ability to maintain blood pressure has been compromised by a reduced blood volume or concurrent administration of certain CNS depressant drugs (eg, phenothiazines or general anesthetics). benzhydrocodone/acetaminophen and prochlorperazine both increase sedation. Avoid or Use Alternate Drug. Limit use to patients for whom alternative treatment options are inadequatebenzphetamineMonitor Closely (2)prochlorperazine, benzphetamine. Mechanism: unknown. Use Caution/Monitor. Risk of cardiac arrhythmia or sudden death, more likely w/thioridazine than other phenothiazines. Interaction more likely in certain predisposed pts. only. prochlorperazine increases and benzphetamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.benztropineMonitor Closely (1)prochlorperazine increases effects of benztropine by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic adverse effects may be seen with concurrent use. .brexanoloneMonitor Closely (1)brexanolone, prochlorperazine. Either increases toxicity of the other by sedation. Use Caution/Monitor.brexpiprazoleMonitor Closely (1)brexpiprazole and prochlorperazine both increase sedation. Use Caution/Monitor.brimonidineMonitor Closely (1)brimonidine and prochlorperazine both increase sedation. Use Caution/Monitor.Minor (1)brimonidine increases effects of prochlorperazine by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS